Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Chemotherapy is the basis of treatment for Hodgkin's lymphoma for most patients and uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body. The standard approach to Hodgkin's lymphoma chemotherapy is treatment with more than one anticancer drug.
Drug combinations are used because different medications damage or kill cancer cells in different ways, making them more vulnerable to the treatment. Drugs added together in lower doses also help reduce the likelihood of side effects without reducing the overall amount of effective chemotherapy. Commonly used regimens are Stanford V (Stanford "Five") and ABVD. For a highly selected group of high risk patients, escalated BEACOPP is used. With the recent FDA approval of brentuximab vedotin (Adcetris), we have trials evaluating this drug in the front-line setting, as well as other small molecules for relapsed disease.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.